A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and duration of tumor control
Chronic Lymphocytic Leukemia
DRUG: GS-1101
Progression-free survival, 18 mon|Patient Well-Being, Health-related quality-of-life questionnaire, 18 months|Disease-related Biomarkers, 18 months|Pharmacokinetics, Evaluation of plasma concentrations at peak (Cmax) and trough (Cmin), 6 months|Incidence of Adverse Events, 18 months|Health Resource Utilization, 18 months
This is a Phase 2, multicenter, single-arm, controlled, clinical trial evaluating the efficacy and safety of the phosphatidylinositol 3-kinase delta (PI3K-delta) inhibitor GS-1101 (CAL-101) as therapy for previously treated chronic lymphocytic leukemia.

This clinical trial (Study GS-US-312-0120) is a single-arm in which compliant subjects from GS US-312-0119 -Arm B who experience progression of CLL while receiving single-agent ofatumumab therapy are potentially eligible to receive single-agent, open-label GS 1101 therapy.